Parkinson's disease (PD) results primarily from the death of dopaminergic neurons in the
substantia nigra. Current PD medications treat symptoms; none halt or retard dopaminergic …

Phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1) and PARK2/Parkin
mutations cause autosomal recessive forms of Parkinson's disease. Upon a loss of …

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) damages the nigrostriatal dopaminergic
pathway as seen in Parkinson's disease (PD), a common neurodegenerative disorder with …

Mutations in superoxide dismutase-1 (SOD1) cause a form of the fatal paralytic disorder
amyotrophic lateral sclerosis (ALS), presumably by a combination of cell-autonomous and non–…

Minocycline mediates neuroprotection in experimental models of neurodegeneration. It
inhibits the activity 1 , 2 , 3 , 4 , 5 , 6 of caspase-1, caspase-3, inducible form of nitric oxide …

MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) damages dopaminergic neurons as
seen in Parkinson disease. Here we show that after administration of MPTP to mice, there …

This protocol describes our method of producing a reliable mouse model of Parkinson's
disease (PD) using the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). We …

Parkinson's disease (PD) is a common neurodegenerative disease that appears essentially
as a sporadic condition. It results mainly from the death of dopaminergic neurons in the …

Mutations in the copper/zinc superoxide dismutase (SOD1) gene produce an animal model
of familial amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disorder. To test a …

Altered degradation of α-synuclein (α-syn) has been implicated in the pathogenesis of
Parkinson disease (PD). We have shown that α-syn can be degraded via chaperone-mediated …